[HTML][HTML] Inflammation and colorectal cancer: a meta-analysis of the prognostic significance of the systemic immune–inflammation index (SII) and the systemic …
The overall prognosis for colorectal cancer (CRC) remains challenging as the survival time
varies widely, even in patients with the same stage of disease. Recent studies suggest …
varies widely, even in patients with the same stage of disease. Recent studies suggest …
Colorectal cancer: Recent advances in management and treatment
H Fadlallah, J El Masri, H Fakhereddine… - World journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second most
common cause of cancer-related death. In 2020, the estimated number of deaths due to …
common cause of cancer-related death. In 2020, the estimated number of deaths due to …
Epidermal growth factor receptor targeting in colorectal carcinoma: antibodies and patient-derived organoids as a smart model to study therapy resistance
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide.
Therefore, the need for new therapeutic strategies is still a challenge. Surgery and …
Therefore, the need for new therapeutic strategies is still a challenge. Surgery and …
Exploring the role of Fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance
Fusobacterium nucleatum (Fn) has been extensively studied for its connection to colorectal
cancer (CRC) and its potential role in chemotherapy resistance. Studies indicate that Fn is …
cancer (CRC) and its potential role in chemotherapy resistance. Studies indicate that Fn is …
Unraveling the complexities of colorectal cancer and its promising therapies–An updated review
S Saha, S Ghosh, S Ghosh, S Nandi… - International …, 2024 - Elsevier
Colorectal cancer (CRC) continues to be a global health concern, necessitating further
research into its complex biology and innovative treatment approaches. The etiology …
research into its complex biology and innovative treatment approaches. The etiology …
[PDF][PDF] Precision medicine and immunotherapy advances transforming colorectal cancer treatment
TA Addissouky, IE El Sayed, MM Ali… - Journal of …, 2024 - researchgate.net
Background Colorectal cancer (CRC) remains one of the most prevalent cancers and
leading causes of cancer mortality worldwide. Global disease burden has risen in tandem …
leading causes of cancer mortality worldwide. Global disease burden has risen in tandem …
[HTML][HTML] Plasma-Derived Extracellular Vesicles and Non-Extracellular Vesicle Components from APCMin/+ Mice Promote Pro-Tumorigenic Activities and Activate …
Colorectal cancer (CRC) is the third most prevalent cancer worldwide. Current studies have
demonstrated that tumor-derived extracellular vesicles (EVs) from different cancer cell types …
demonstrated that tumor-derived extracellular vesicles (EVs) from different cancer cell types …
Resistance to 5-fluorouracil: The molecular mechanisms of development in colon cancer cells
N Radenković, D Nikodijević, J Jovankić… - European journal of …, 2024 - Elsevier
Colon cancer is a significant health problem worldwide as it is one of the most common and
deadliest cancers. The standard approach for the treatment of colon cancer is 5-fluorouracil …
deadliest cancers. The standard approach for the treatment of colon cancer is 5-fluorouracil …
NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets
Colorectal cancer (CRC) is currently ranked as the third most common type of cancer,
contributing significantly to mortality and morbidity worldwide. Epigenetic and genetic …
contributing significantly to mortality and morbidity worldwide. Epigenetic and genetic …
[HTML][HTML] The roles of rac1 and rac1b in colorectal cancer and their potential contribution to cetuximab resistance
CC Wahoski, B Singh - Cancers, 2024 - mdpi.com
Simple Summary Cetuximab is a treatment widely used to treat advanced, metastatic
colorectal cancer (CRC), and it works by blocking epidermal growth factor receptor …
colorectal cancer (CRC), and it works by blocking epidermal growth factor receptor …